Drug releasing coatings for medical devices

• US 8,403,910 B2
• Filed: 03/07/2011
• Issued: 03/26/2013
• Est. Priority Date: 11/20/2006
• Status: Active Grant

• Current Assignee: Lutonix, Inc. (Becton, Dickinson & Co)
• Original Assignee: Lutonix, Inc. (Becton, Dickinson & Co)
• Inventors: Wang, Lixiao
• Primary Examiner(s): ZISKA, SUZANNE E
• Application Number:
  US13/042,213
• Publication Number:
  US 20110166548A1
• Time in Patent Office: 750 Days
• Field of Search: None
• US Class Current: 604/509
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/436 the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61L 2300/216 with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
• CPC Class Codes: A61L 2300/416 Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
• CPC Class Codes: A61L 2300/428 Vitamins, e.g. tocopherol, riboflavin
• CPC Class Codes: A61L 2300/608 having two or more layers
• CPC Class Codes: A61L 2300/802 Additives, excipients, e.g. cyclodextrins, fatty acids, surfactants
• CPC Class Codes: A61L 2420/06 Coatings containing a mixture of two or more compounds
• CPC Class Codes: A61L 2420/08 Coatings comprising two or more layers
• CPC Class Codes: A61L 29/08 Materials for coatings
• CPC Class Codes: A61L 29/085 Macromolecular materials
• CPC Class Codes: A61L 29/16 Biologically active materials, e.g. therapeutic substances A61L29/048 takes precedence
• CPC Class Codes: A61L 29/18 Materials at least partially X-ray or laser opaque
• CPC Class Codes: A61L 31/16 Biologically active materials, e.g. therapeutic substances A61L31/047 takes precedence
• CPC Class Codes: A61L 31/18 Materials at least partially X-ray or laser opaque
• CPC Class Codes: A61M 2025/105 having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
• CPC Class Codes: A61M 2210/1025 Respiratory system A61M2210/0618 take precedence
• CPC Class Codes: A61M 25/10 Balloon catheters A61M25/0125 takes precedence; embolectomy A61B17/22032; retractors A61B17/02; inflatable balloons for placing stents or stent-grafts A61F2/958 ; stomach balloons for treatment of obesity A61F5/0003; oesophagal tubes A61J15/00
• CPC Class Codes: A61P 11/00 : Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 : Antiasthmatics
• CPC Class Codes: A61P 29/00 : Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/02 : Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 35/00 : Antineoplastic agents
• CPC Class Codes: A61P 37/06 : Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 7/02 : Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system

Abstract

The invention relates to a medical device for delivering a therapeutic agent to a tissue. The medical device has a layer overlying the exterior surface of the medical device. The layer contains a therapeutic agent and an additive. The additive has a hydrophilic part and a hydrophobic part and the therapeutic agent is not enclosed in micelles or encapsulated in particles or controlled release carriers.

Claims

1. A method for treating a blood vessel, the method comprising:

inserting a balloon catheter into the blood vessel, the balloon catheter comprising;

an inflatable polyamide balloon; and

a coating layer that adheres to an exterior surface of the inflatable polyamide balloon,

wherein;

the coating layer comprises a hydrophobic therapeutic agent and a water-soluble additive;

the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, everolimus, docetaxel, and combinations thereof;

the hydrophobic therapeutic agent is not enclosed in micelles or liposomes and is not encapsulated in polymer particles;

the water-soluble additive comprises a PEG fatty ester selected from the group consisting of PEG laurates, PEG oleates, PEG stearates, PEG glyceryl laurates, PEG glyceryl oleates, PEG glyceryl stearates, PEG sorbitan monolaurates, PEG sorbitan monooleates, PEG sorbitan stearates, PEG sorbitan laurates, PEG sorbitan oleates, and PEG sorbitan palmitates;

the ratio by weight of the at least one additive to the therapeutic agent in the coating layer is from about 0.05 to 100;

inflating the balloon catheter to press the coating layer into contact with walls of the blood vessel during a balloon inflation time of 2 minutes or less;

releasing a therapeutically effective amount of the therapeutic agent from the inflated balloon catheter to the walls of the blood vessel during the balloon inflation time;

deflating the inflated balloon catheter in the blood vessel at the end of the balloon inflation time; and

withdrawing the deflated balloon catheter from the blood vessel.

2. The method of claim 1, wherein the water-soluble additive is selected from a group consisting of PEG-8 laurate, PEG-8 oleate, PEG-8 stearate, PEG-9 oleate, PEG-10 laurate, PEG-10 oleate, PEG-12 laurate, PEG-12 oleate, PEG-15 oleate, PEG-20 laurate, PEG-20 oleate, PEG-20 dilaurate, PEG-20 dioleate, PEG-20 distearate, PEG-32 dilaurate and PEG-32 dioleate, and PEG-20 sorbitan monolaurate, PEG-20 sorbitan monopalmitate, PEG-20 sorbitan monostearate, and PEG-20 sorbitan monooleate.

3. The method of claim 1, wherein the water-soluble additive is selected from the group consisting of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monopalmitate, PEG-20 sorbitan monostearate, and PEG-20 sorbitan monooleate.

4. The method of claim 1, wherein the water-soluble additive is selected from the group consisting of PEG-20 sorbitan monolaurate and PEG-20 sorbitan monooleate.

5. The method of claim 1, wherein the concentration of the therapeutic agent in the coating layer is from 1 μ

g/mm² to 20 μ

g/mm².

6. The method of claim 1, wherein the concentration of the water-soluble additive in the coating layer is from 1 μ

g/mm² to 10 μ

g/mm².

7. The method of claim 1, wherein the ratio by weight of the water-soluble additive to the therapeutic agent in the coating layer is from about 0.5 to 2.

8. The method of claim 1, wherein the balloon catheter is a perfusion balloon catheter, a cutting balloon catheter, or a scoring balloon catheter.

9. The method of claim 1, wherein the balloon catheter further comprises a dimethylsulfoxide solvent layer overlying the coating layer.

10. The method of claim 1, wherein the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel and rapamycin.

11. The method of claim 1, wherein the hydrophobic therapeutic agent is paclitaxel.

12. The method of claim 1, wherein:

the hydrophobic therapeutic agent is paclitaxel; and

the water-soluble additive is selected from the group consisting of PEG-20 sorbitan monolaurate and PEG-20 sorbitan monooleate.

13. The method of claim 1, wherein the coating layer does not include an iodine covalent bonded contrast agent, oil, or a lipid.

14. The method of claim 1, wherein the coating layer does not include a polymer.

15. The method of claim 1, further comprising:

crimping a stent over the coated balloon of the balloon catheter before inserting the balloon catheter into the body passage.

17. The method of claim 6, wherein removing plaque from the target site of the blood vessel comprises removing the plaque by one of a debulking catheter, a laser atherectomy, a directing atherectomy, or a rotational atherectomy.

16. A method for treating a blood vessel, the method comprising:

removing plaque from a target site of the blood vessel;

inserting a balloon catheter into the blood vessel to the target site, the balloon catheter comprising;

an inflatable polyamide balloon; and

a coating layer that adheres to an exterior surface of the inflatable polyamide balloon,

wherein;

the coating layer comprises a hydrophobic therapeutic agent and at least one water-soluble additive;

the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, everolimus, docetaxel, and combinations thereof;

the hydrophobic therapeutic agent is not enclosed in micelles or liposomes and is not encapsulated in polymer particles;

the at least one water-soluble additive comprises a PEG fatty ester selected from the group consisting of PEG laurates, PEG oleates, PEG stearates, PEG glyceryl laurates, PEG glyceryl oleates, PEG glyceryl stearates, PEG sorbitan monolaurates, PEG sorbitan monooleates, PEG sorbitan stearates, PEG sorbitan laurates, PEG sorbitan oleates, and PEG sorbitan palmitates;

the ratio by weight of the at least one additive to the therapeutic agent in the coating layer is from about 0.05 to 100;

inflating the balloon catheter to press the coating layer into contact with walls of the blood vessel during a balloon inflation time of 2 minutes or less;

releasing a therapeutically effective amount of the therapeutic agent from the inflated balloon catheter to the walls of the blood vessel during the balloon inflation time;

deflating the inflated balloon catheter in the blood vessel at the end of the balloon inflation time; and

withdrawing the deflated balloon catheter from the blood vessel.

18. The method of claim 16, wherein the balloon catheter is inserted into the blood vessel after the plaque is removed.

19. The method of claim 16, further comprising:

crimping a stent over the coated balloon of the balloon catheter before inserting the balloon catheter into the blood vessel.

20. The method of claim 16, wherein the water-soluble additive is selected from the group consisting of PEG-20 sorbitan monolaurate and PEG-20 sorbitan monooleate.

21. The method of claim 16, wherein the concentration of the therapeutic agent in the coating layer is from 1 μ

g/mm² to 20 μ

g/mm².

22. The method of claim 16, wherein the ratio by weight of the water-soluble additive to the therapeutic agent in the coating layer is from about 0.1 to 5.

23. The method of claim 16, wherein the balloon catheter is a perfusion balloon catheter, a cutting balloon catheter, or a scoring balloon catheter.

24. The method of claim 16, wherein the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, and combinations thereof.

25. The method of claim 16, wherein the hydrophobic therapeutic agent is paclitaxel.

26. The method of claim 16, wherein:

the hydrophobic therapeutic agent is paclitaxel; and

the water-soluble additive is selected from the group consisting of PEG-20 sorbitan monolaurate and PEG-20 sorbitan monooleate.

27. The method of claim 16, wherein the coating layer does not include an iodine covalent bonded contrast agent, oil, or a lipid.

28. The method of claim 16, wherein the coating layer does not include a polymer.

29. A method for treating tissue in a body passage of a body, the method comprising:

inserting a balloon catheter into the body passage, the balloon catheter comprising;

an inflatable polyamide balloon; and

a coating layer that adheres to an exterior surface of the inflatable polyamide balloon,

wherein;

the coating layer comprises a hydrophobic therapeutic agent and at least one water-soluble additive;

the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel, rapamycin, everolimus, docetaxel, and combinations thereof;

the hydrophobic therapeutic agent is not enclosed in micelles or liposomes and is not encapsulated in polymer particles;

the at least one water-soluble additive comprises a PEG fatty ester selected from the group consisting of PEG laurates, PEG oleates, PEG stearates, PEG glyceryl laurates, PEG glyceryl oleates, PEG glyceryl stearates, PEG sorbitan monolaurates, PEG sorbitan monooleates, PEG sorbitan stearates, PEG sorbitan laurates, PEG sorbitan oleates, and PEG sorbitan palmitates;

the ratio by weight of the at least one additive to the therapeutic agent in the coating layer is from about 0.05 to 100;

inflating the balloon catheter to contact the coating layer with the tissue in the body passage during a balloon inflation time of 2 minutes or less;

releasing a therapeutically effective amount of the therapeutic agent from the inflated balloon catheter to the tissue in the body passage during the balloon inflation time;

deflating the inflated balloon catheter in the body passage at the end of the balloon inflation time; and

withdrawing the deflated balloon catheter from the body passage.

30. The method of claim 29, wherein the tissue is selected from the group consisting of coronary vasculature tissue, peripheral vasculature tissue, cerebral vasculature tissue, esophageal tissue, pulmonary airway tissue, sinus tissue, tracheal tissue, colon tissue, biliary tract tissue, urinary tract tissue, prostate tissue, and brain passage tissue.

31. The method of claim 29, further comprising:

crimping a stent over the coated balloon of the balloon catheter before inserting the balloon catheter into the body passage.

32. The method of claim 29, wherein the water-soluble additive is selected from the group consisting of PEG-20 sorbitan monolaurate, PEG-20 sorbitan monopalmitate, PEG-20 sorbitan monostearate, and PEG-20 sorbitan monooleate.

33. The method of claim 29, wherein the water-soluble additive is selected from the group consisting of PEG-20 sorbitan monolaurate and PEG-20 sorbitan monooleate.

34. The method of claim 29, further comprising a dimethylsulfoxide solvent layer overlying the coating layer.

35. The method of claim 29, wherein the hydrophobic therapeutic agent is selected from the group consisting of paclitaxel and rapamycin.

36. The method of claim 29, wherein:

the hydrophobic therapeutic agent is paclitaxel; and

the water-soluble additive is selected from the group consisting of PEG-20 sorbitan monolaurate and PEG-20 sorbitan monooleate.